A group of doctors inspired by Memorial Sloan-Kettering’s decision not to carry a new colorectal cancer drug (Zaltrap®) due to its cost banded together in hopes of persuading some leading pharmaceutical companies to bring prices down.
A group of more than 100 influential cancer specialists, inspired by Memorial Sloan-Kettering’s decision not to carry a new colorectal cancer drug due to its cost, have banded together in hopes of persuading some leading pharmaceutical companies to bring prices down.
Epidemiologist Helena Furberg commented on a study that found that men who are overweight are more likely to have precancerous lesions detected in a benign prostate biopsy and are at a greater risk for subsequently developing prostate cancer.
Interventional radiologist Constantinos Sofocleous discussed a study he led that found that irreversible electroporation, a technique that sends electrical pulses via tiny needles directly to tumors, successfully destroys cancer cells without harming nearby healthy cells.
Gynecologist and geneticist Noah Kauff commented on a study that found that women diagnosed with uterine cancer may have a higher risk of developing colon cancer later in life. He said the increased risk could be due to women with a hereditary condition known as Lynch syndrome.
Visible Ink founder Judith Kelman discussed the Memorial Sloan-Kettering program she runs that connects patients with experienced writers, editors, and teachers to help them tell their stories in writing. A Memorial Sloan-Kettering patient and program participant was also interviewed.
Endocrinologist James Fagin spoke about a study he led that found that an investigational drug may help some patients with thyroid cancer who are unable to absorb radioactive iodine, the most effective therapy for the disease.